Matthew Strobeck - 02 Jan 2026 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Director
Signature
/s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck
Issuer symbol
BDSX
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 16:27:01 UTC
Previous filing
02 Jun 2025
Next filing
13 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Strobeck Matthew Director 919 WEST DILLON RD, LOUISVILLE /s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck 06 Jan 2026 0001377832

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Award $0 +6,804 $0.000000 6,804 02 Jan 2026 Common Stock 6,804 Direct F1, F2, F3
transaction BDSX Stock Options (Right to Buy) Award $0 +6,354 $0.000000 6,354 02 Jan 2026 Common Stock 6,354 $6.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
F2 These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F3 Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
F4 This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.